Recommendation of the President – Alyftrek (deutiwakaftor, tezakaftor, wanzakaftor)
On 17 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 24/2026 on the reimbursement of the medicinal product Alyftrek (deutiwakaftor, tezakaftor, wanzakaftor) under the B.112 drug program. “Treatment of patients with cystic fibrosis (ICD-10: E84)”